Benitec Biopharma Inc. (BNTC): Total Assets
$182.62M
As of 2026-06-30
+244.6%
3-year compound annual growth
+53.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $182.62M | +83.4% | 2026-09-14, Balance as of period end |
| 2025-06-30 | $99.59M | +90.8% | 2026-09-14, Balance as of period end |
| 2024-06-30 | $52.21M | n/m | 2026-03-20, Balance as of period end |
| 2023-06-30 | $4.46M | -25.3% | 2024-09-26, Balance as of period end |
| 2022-06-30 | $5.97M | -72.1% | 2023-09-21, Balance as of period end |
| 2021-06-30 | $21.38M | +84.5% | 2022-09-02, Balance as of period end |
| 2020-06-30 | $11.59M | -39.8% | 2021-09-20, Balance as of period end |
| 2019-06-30 | $19.23M | n/a | 2020-09-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $182.62M | +83.4% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $184.69M | +4.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $185.55M | +28.7% |
| PepGen Inc. (PEPG) | 2025-12-31 | $173.91M | +15.3% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $192.35M | -12.7% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $193.44M | +74.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $169.01M | -4.7% |
Compare BNTC, ANRO, LXRX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗